Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).

被引：0
|
作者：
Cremolini, Chiara
Loupakis, Fotios
Yang, Dongyun
Salvatore, Lisa
Zhang, Wu
Wakatsuki, Takeru
Schirripa, Marta
Lonardi, Sara
Antoniotti, Carlotta
Aprile, Giuseppe
Masi, Gianluca
Graziano, Francesco
Ruzzo, Annamaria
Lucchesi, Sara
Ronzoni, Monica
Maus, Martin Karl Herbert
Bocci, Guido
Tonini, Giuseppe
Falcone, Alfredo
Lenz, Heinz-Josef
机构：
[1] Azienda Osped Univ Pisana, UO Oncol Med 2, Ist Toscano Tumori, Pisa, Italy
[2] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[3] IRCCS, Ist Oncolog Veneto, Padua, Italy
[4] Azienda Osped Univ Udine, Udine, Italy
[5] UOC Oncol AO, Pesaro, Italy
[6] Univ Urbino, Sect Biochem & Mol Biol, Dept Biomol Sci, I-61029 Urbino, Italy
[7] Osped Pontedera, UO Oncol Med, Pontedera, Italy
[8] Ist Sci San Raffaele, Dipartimento Oncol, Milan, Italy
[9] Response Genet Inc, Los Angeles, CA USA
[10] Univ Pisa, Div Chemotherapy & Pharmacol, Dept Internal Med, Pisa, Italy
[11] Univ Campus Biomed, Rome, Italy
[12] Univ Pisa, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3518
引用
收藏
页数：1
相关论文
共 50 条
  • [41] MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).
    Lenz, Heinz-Josef
    Lee, Fa-Chyi
    Yau, Linda
    Koh, Han A.
    Knost, James A.
    Mitchell, Edith P.
    Bosanac, Ivan
    Mancao, Christoph
    Parikh, Aparna
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [42] Amphiregulin (AREG) expression and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).
    Kohne, Claus-Henning
    Hofheinz, Ralf
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Twomey, Brian
    Oliner, Kelly Smith
    Boedigheimer, Michael
    Terwey, Jan-Henrik
    Karthaus, Meinolf
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [43] Expression of amphiregulin (AREG) and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).
    Kohne, Claus-Henning
    Hofheinz, Ralf D.
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Twomey, Brian
    Oliner, Kelly Smith
    Boedigheimer, Michael
    Terwey, Jan-Henrik
    Karthaus, Meinolf
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Impact of primary tumour location (PTL) on outcomes in patients (pts) with metastatic colorectal cancer (mCRC) undergoing first-line panitumumab (Pmab) plus FOLFIRI treatment
    Karthaus, Meinolf
    Van Den Eynde, Marc
    Mineur, Laurent
    Thaler, Josef
    Koukakis, Reija
    Berkhout, Marloes
    Gallego, Javier
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [45] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [46] SINGLE INSTITUTION RESULTS OF FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER (MCRC)
    Barkmanova, Jaroslava
    Petruzelka, Lubos
    Sedlackova, Eva
    Vocka, Michal
    Hejduk, Karel
    Bortlicek, Zbynek
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [47] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Safety analysis of first-line bevacizumab plus chemotherapy in patients with metastatic colorectal cancer (mCRC) participating in a US registry
    Kozloff, M.
    Cohn, A.
    Christiansen, N.
    Flynn, P.
    Kabbinavar, F.
    Robles, R.
    Ulcickas-Yood, M.
    Sarkar, S.
    Hambleton, J.
    Grothey, A.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 173 - 173
  • [49] Relevance of neo- or adjuvant pretreatment in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab as first-line treatment - data from the prospective TKK registry
    Schnell, R.
    Trarbach, T.
    Broszeit-Luft, S.
    Musch, R.
    Wetzel, N.
    Kopfmann, S.
    Jaenicke, M.
    Marschner, N.
    [J]. Oncology Research and Treatment, 2015, 38 : 114 - 114
  • [50] Use of genetic variants to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)
    Singh, H.
    Pohl, A.
    El-Khoueiry, A.
    Lurje, G.
    Zhang, W.
    Yang, D.
    Ning, Y.
    Shriki, J.
    Iqbal, S.
    Lenz, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345